Akari Therapeutics
24 West 40th Street. 8th Floor
New York
New York
10018
United States
Tel: 1-646-350-0702
Fax: 1-646-843-9352
Website: http://akaritx.com/
117 articles with Akari Therapeutics
-
Akari Therapeutics Narrows Pipeline Focus
8/1/2022
Akari Therapeutics, Plc, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announced that it is prioritizing two pipeline programs.
-
Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy
7/28/2022
Akari Therapeutics, Plc today announced positive results from recent pre-clinical studies on the tolerability and extended dose interval of long-acting PAS-nomacopan in development for geographic atrophy (GA) in dry age-related macular degeneration (dAMD).
-
Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
7/20/2022
Akari Therapeutics, Plc announced financial results for the quarter ended March 31, 2022, as well as research and development progress on nomacopan and long-acting PAS-nomacopan.
-
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
7/7/2022
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced that a patient has completed the course of investigational nomacopan treatment in the open-label, multi-center Phase III Part A clinical trial in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).
-
This week's Movers & Shakers includes a number of chief business officers and business development leaders alongside those tapped for scientific roles.
-
Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies
6/13/2022
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of Melissa Bradford-Klug as Chief Operating Officer, effective July 1, 2022.
-
Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting
5/19/2022
Akari Therapeutics, Plc presented results from the CASCADE and CORONET studies in patients with COVID-19 pneumonia at the American Thoracic Society 2022 Annual Meeting.
-
Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress
5/16/2022
Akari Therapeutics, Plc, a late-stage biotechnology company focused on advanced therapies for autoimmune and inflammatory diseases, announced financial results for the full year ended December 31, 2021, as well as recent pipeline progress.
-
Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting
5/11/2022
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced that two posters will be presented at the American Thoracic Society (ATS) 2022 Annual Meeting reporting results from the CORONET and CASCADE studies in patients with COVID-19 pneumonia.
-
Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology
5/10/2022
Akari Therapeutics, plc (Nasdaq: AKTX), a late-stage biotechnology company focused on development of advanced therapies for autoimmune and inflammatory diseases, announced positive results from the Phase II study of investigational nomacopan in bullous pemphigoid (BP) were published online in the Journal of the American Medical Association (JAMA) Dermatology.
-
Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)
5/9/2022
Akari Therapeutics, plc (Nasdaq: AKTX), a late-stage biotechnology company focused on the development of advanced therapies for autoimmune and inflammatory diseases, presented positive results from two preclinical studies of its lead asset, investigational nomacopan, in diseases of the eye at the Association of Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting.
-
Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
3/21/2022
Akari Therapeutics, Plc today announced that Professor Virginia Calder, Professor of Ocular Inflammation, The Institute of Ophthalmology, UCL and Moorfields Eye Hospital, London, UK and Akari Therapeutics will be giving an oral and poster presentation at the ARVO 2022 Annual Meeting.
-
Akari announced that votucalis has potential as a treatment for pain and itch associated with conditions such as atopic dermatitis, psoriasis and neuropathic pain.
-
Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch
3/9/2022
Akari Therapeutics, Plc today announced new preclinical data published in Frontiers in Pharmacology demonstrating that Akari’s pipeline candidate votucalis has potential as a treatment for pain and itch associated with conditions such as atopic dermatitis, psoriasis and neuropathic pain.
-
Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering
3/8/2022
Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), today announced that it has entered into definitive agreements with certain institutional investors, accredited investors, and Dr. Ray Prudo, Akari’s Chairman, to receive gross proceeds of approximately $9.0 million.
-
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer
3/2/2022
Akari Therapeutics, Plc, a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and/or leukotriene systems are implicated, announced the appointment of Rachelle Jacques as President and Chief Executive Officer of Akari Therapeutics.
-
Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma
2/28/2022
Akari Therapeutics, Plc (Nasdaq: AKTX), today announced new data showing that clinical outcomes in U.S. Army trauma patients correlate with complement activation, and that nomacopan significantly improves survival from 30% to 80% in a clinically relevant preclinical model of traumatic hemorrhage.
-
Akari Therapeutics to Present at BIO CEO & Investor Conference
2/11/2022
Akari Therapeutics, Plc announced that Clive Richardson, Chief Executive Officer of Akari Therapeutics, will present a company overview during the BIO CEO & Investor Conference on Tuesday, February 15, 2022 at 2:30 p.m. ET, at the New York Marriott Marquis.
-
Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases
1/26/2022
Akari Therapeutics, Plc today announced further development of a program for the inhaled delivery of nomacopan to the lung, working with Inhalation Sciences AB to refine dosing and pharmacokinetics of nomacopan for both dry powder and nebulized delivery.
-
FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies
1/19/2022
Akari Therapeutics, Plc, a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and/or leukotriene systems are implicated, announced that the U.S. Food and Drug Administration has agreed, via a Type C meeting, to the clinical use of nomacopan derived from a next generation manufacturing process.